BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

FDA Panel Votes To Let Merck & Co., Inc.'s (MRK) Vioxx Sales Resume; Panel Says Pfizer Inc.'s (PFE) Celebrex And Bextra To Remain On Market


10/19/2005 5:12:47 PM

A U.S. Food and Drug Administration advisory panel narrowly agreed Friday that Merck's recalled drug Vioxx was safe enough to be sold, and cleared the way for Pfizer's Celebrex and Bextra to remain on the market. The 17-15 ruling paves the way for Merck (MRK: news, chart, profile) to bring the controversial painkiller back to pharmacies. On Thursday, the company said it is considering a comeback for the drug, which was pulled from the market in September over concerns of heart risk. The matter still must get a final OK from the FDA, but the agency generally always heeds the recommendations of its expert panels. The news sent Merck shares skyward by $3.76, or 13 percent, to $32.61 at the close. A company spokeswoman said Merck would not comment on the vote. Meeting for three days on whether Vioxx and other so-called Cox-2 inhibitors should be on the market, panelists also voted 31-1 to keep Pfizer's Celebrex -- also in the same class of drugs -- on the market. Voting was tighter on Bextra, 17-13 in favor of keeping it on the market. The news sent shares of Pfizer (PFE: news, chart, profile) higher by $1.74, or 6.9 percent, to $26.80. All three drugs, though, were determined to cause heart risk by the panel in a unanimous vote. And a majority of panelists indicated they supported warning labels for all three, but did not take a formal vote on that matter. The warning would disclose risks to patients of possible cardiovascular problems.

Read at Reuters
Read at Reuters
Read at CBS MarketWatch
Read at AP
Read at AP

Reuters
Reuters
CBS MarketWatch
AP
AP
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->